focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 250 movers: Miners drag index down, Synthomer spikes higher

Tue, 11th Aug 2015 14:15

(ShareCast News) - The FTSE 250 index was by late on Tuesday afternoon giving up some of the gains made late the day before, as commodities-focused stocks were hit by China's devaluation and corporate news received mixed reviews.By 1540 BST the index was down 0.47% at 17,677.29 points, with Vedanta Resources losing most of the ground that it had gained on Monday.Other mid-cap basic resources hit as the dollar appreciated 1.8% against China's yuan included copper producer Kaz Minerals, Premier Oil and platinum miner Lonmin.Although its shares gained initially, Just Retirement was firmly in the red later in the day after agreeing a 60-40 merger in its favour with annuities rival Partnership Assurance to create a new £1.7bn company.Woodford Patient Capital Trust, one of the funds run by star fund manager Neil Woodford, was lower despite after publishing first half-year results since listing in April this year, with the shares trading at an 11% premium to net assets value per share. But the shares were hit by the announcement of a tap issuance programme to satisfy excess demand in the secondary market, but the new shares issued will be done so at a premium to NAV and should therefore be accretive to existing shareholders.Building materials group SIG fell despite posting a rise in first-half pre-tax profit and raising its interim dividend. The company said its margins were under pressure, with variable trading conditions in Europe and a significant weakening of the euro which hit revenues.Leading the 250 risers on Tuesday was Synthomer, as the latex maker reported a first-half profit before tax of £51.4m, up 14% from the first half of last year. The company said the performance was strong given significant exchange rate headwinds, and warned its full year result could suffer if conditions continued.Online and catalogue retailer N Brown was lifted despite the release of mixed UK retail sales data from the BRC. Online non-food sales rose by 14.7%, higher than expected, but ladieswear had a disappointing month, though accessories, kidswear and summer footwear enjoyed strong sales.Allied Minds, after being revealed as one of the stocks in the Woodford Patient Capital Trust's top ten holdings, was another big gainer. (4d Pharma and Vernalis, an AIM company, also gained strongly later in the session, though Imperial Innovations was a faller, disproving any Woodford-based stock picking strategies.)FTSE 250 - RisersSynthomer (SYNT) 350.80p +6.40%Allied Minds (ALM) 471.50p +5.88%Zoopla Property Group (WI) (ZPLA) 257.90p +5.65%Nostrum Oil & Gas (NOG) 570.00p +3.92%Euromoney Institutional Investor (ERM) 1,115.00p +3.82%Cineworld Group (CINE) 550.00p +3.38%Centamin (DI) (CEY) 55.05p +2.42%Evraz (EVR) 97.75p +2.20%Brown (N.) Group (BWNG) 322.00p +2.09%Acacia Mining (ACA) 241.20p +1.99%FTSE 250 - FallersVedanta Resources (VED) 468.00p -4.76%Shawbrook Group (SHAW) 324.60p -4.36%Kaz Minerals (KAZ) 156.70p -3.81% Just Retirement Group (JRG) 191.20p -3.77%Woodford Patient Capital Trust (WPCT) 115.50p -3.19%Premier Oil (PMO) 119.50p -3.00%Lonmin (LMI) 43.05p -2.93%SIG (SHI) 196.10p -2.58%Brewin Dolphin Holdings (BRW) 301.00p -2.40%Ocado Group (OCDO) 374.30p -2.32%
More News
24 May 2021 09:42

More positive data reported from 4D Pharma trial of 'Blautix'

(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced additional positive data from its completed phase 2 trial of 'LBP Blautix' on Monday, in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhea (IBS-D).

Read more
24 May 2021 09:20

4d Pharma posts more "positive" results from Blautix probe

4d Pharma posts more "positive" results from Blautix probe

Read more
17 May 2021 16:05

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
19 Apr 2021 10:50

4D Pharma forms partnership with Parkinson's UK to improve treatments

4D Pharma forms partnership with Parkinson's UK to improve treatments

Read more
16 Apr 2021 15:17

DIRECTOR DEALINGS: Tesco chair invests GBP100,000; Dechra exec sells

DIRECTOR DEALINGS: Tesco chair invests GBP100,000; Dechra exec sells

Read more
1 Apr 2021 12:00

TRADING UPDATES: 4D Pharma loss widens on rise in administrative costs

TRADING UPDATES: 4D Pharma loss widens on rise in administrative costs

Read more
22 Mar 2021 09:25

4D Pharma completes reversal into Nasdaq listing via US Spac

4D Pharma completes reversal into Nasdaq listing via US Spac

Read more
17 Mar 2021 18:40

TRADING UPDATES: Ceres Power eyes move to Main Market by mid-2022

TRADING UPDATES: Ceres Power eyes move to Main Market by mid-2022

Read more
11 Mar 2021 16:11

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
1 Mar 2021 16:41

EXECUTIVE CHANGES: New CFOs for Sensyne, Focusrite, Bango, 4D Pharma

EXECUTIVE CHANGES: New CFOs for Sensyne, Focusrite, Bango, 4D Pharma

Read more
1 Mar 2021 14:33

4D Pharma taps John Beck as its new finance chief

(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced the appointment of John Beck as its chief financial officer and member of its management team on Monday.

Read more
1 Mar 2021 14:33

4D Pharma taps John Beck as its new finance chief

(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced the appointment of John Beck as its chief financial officer and member of its management team on Monday.

Read more
1 Mar 2021 10:14

IN BRIEF: 4D Pharma appoints former Ritter finance chief as own CFO

IN BRIEF: 4D Pharma appoints former Ritter finance chief as own CFO

Read more
26 Feb 2021 10:26

4D Pharma Registration Statements Effective; Longevity Buy Progresses

4D Pharma Registration Statements Effective; Longevity Buy Progresses

Read more
8 Feb 2021 16:25

4D Pharma inks collaboration with Merck and Pfizer

(Sharecast News) - Biotherapeutics developer 4D Pharma announced a clinical trial collaboration and supply agreement with Merck and Pfizer on Monday, for 'Bavencio', or avelumab).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.